Michael J. Darsley

1.6k total citations
36 papers, 1.2k citations indexed

About

Michael J. Darsley is a scholar working on Infectious Diseases, Endocrinology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael J. Darsley has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 15 papers in Endocrinology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael J. Darsley's work include Viral gastroenteritis research and epidemiology (18 papers), Escherichia coli research studies (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Michael J. Darsley is often cited by papers focused on Viral gastroenteritis research and epidemiology (18 papers), Escherichia coli research studies (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Michael J. Darsley collaborates with scholars based in United States, United Kingdom and Sweden. Michael J. Darsley's co-authors include Anthony R. Rees, David A. Sack, A. Louis Bourgeois, Barbara DeNearing, A. Keith Turner, Clayton Harro, Pedro Paz, Brian J. Sutton, Richard I. Walker and Subhra Chakraborty and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Experimental Medicine.

In The Last Decade

Michael J. Darsley

36 papers receiving 1.2k citations

Peers

Countries citing papers authored by Michael J. Darsley

Since Specialization

Citations

This map shows the geographic impact of Michael J. Darsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Darsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Darsley more than expected).

Fields of papers citing papers by Michael J. Darsley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Darsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Darsley. The network helps show where Michael J. Darsley may publish in the future.

Co-authorship network of co-authors of Michael J. Darsley

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Darsley. A scholar is included among the top collaborators of Michael J. Darsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Darsley. Michael J. Darsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical development of a novel Group B Streptococcus (GBS) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp) 2023 ·Birth Defects Research ·(unknown), (unknown), (unknown), Michael J. Darsley, Per B. Fischer	9
2	A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains 2022 ·Cell Reports Medicine ·A Pawłowski, Jonas Lannergård, (unknown), Duojia Cao, Sara Larsson, Jenny Persson, (unknown), Michael J. Darsley, Ane Lilleøre Rom, Morten Hedegaard, Per B. Fischer, Bengt Johansson‐Lindbom	23
3	Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women 2021 ·Vaccine ·Per B. Fischer, A Pawłowski, Duojia Cao, David Bell, (unknown), Michael J. Darsley, Bengt Johansson‐Lindbom	37
4	Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection 2019 ·npj Vaccines ·Subhra Chakraborty, Arlo Randall, Tim J. Vickers, (unknown), Clayton Harro, Barbara DeNearing, Jessica Brubaker, David A. Sack, A. Louis Bourgeois, Philip L. Felgner, Xiaowu Liang, Sachin Mani, (unknown), R. Reid Townsend, Petra Erdmann-Gilmore, Michael J. Darsley, David A. Rasko, James M. Fleckenstein	26
5	Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge 2019 ·Vaccine ·Clayton Harro, A. Louis Bourgeois, David A. Sack, Richard I. Walker, Barbara DeNearing, Jessica Brubaker, Nicole Maier, Alan Fix, Len Dally, Subhra Chakraborty, John D. Clements, (unknown), Michael J. Darsley	59
6	An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli 2016 ·PLoS ONE ·Chad K. Porter, Mark S. Riddle, (unknown), David A. Sack, Clayton Harro, Subhra Chakraborty, Ramiro L. Gutiérrez, Stephen J. Savarino, Michael J. Darsley, Robin McKenzie, Barbara DeNearing, Hans Steinsland, David R. Tribble, A. Louis Bourgeois	30
7	Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate 2013 ·Vaccine ·Manjari Lal, (unknown), (unknown), Richard I. Walker, (unknown), James A. Brown, (unknown), Michael J. Darsley, Debra Kristensen, Dexiang Chen	20
8	Caught in the Act: In Vivo Development of Macrolide Resistance to Campylobacter jejuni Infection 2010 ·Journal of Clinical Microbiology ·Janet C. Lindow, Frédéric Poly, David R. Tribble, Patricia Guerry, Marya P. Carmolli, Shahida Baqar, Chad K. Porter, (unknown), Michael J. Darsley, Katrin S. Sadigh, (unknown), Beth D. Kirkpatrick	14
9	A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC 2008 ·Vaccine ·Robin McKenzie, Michael J. Darsley, (unknown), Roger Randall, (unknown), (unknown), Mariel M. Finucane, R. Bradley Sack, Eric R. Hall, A. Louis Bourgeois	33
10	Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation 2007 ·Gut ·Andrew J. Daley, Roger Randall, Michael J. Darsley, Naheed Choudhry, (unknown), Ian R. Sanderson, Nicholas M. Croft, Paul Kelly	24
11	Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers 2005 ·Vaccine ·(unknown), Eric R. Hall, Roger Randall, R. McKenzie, Frederick J. Cassels, (unknown), (unknown), Philip Bedford, Michael J. Darsley, (unknown), (unknown), R. Bradley Sack, David A. Sack, Haitao Chang, (unknown), A. Louis Bourgeois	36
12	Construction and Characterization of Genetically Defined aro omp Mutants of Enterotoxigenic Escherichia coli and Preliminary Studies of Safety and Immunogenicity in Humans 2001 ·Infection and Immunity ·A. Keith Turner, Tamsin D. Terry, David A. Sack, (unknown), Michael J. Darsley	56
13	Immunisation with Phage Displaying Peptides Representing Single Epitopes of the Glycoprotein G Can Give Rise to Partial Protective Immunity to HSV-2 2000 ·Virology ·Anna M. Grabowska, R. Jennings, P. Laing, Michael J. Darsley, Claire L. Jameson, Lonnie P. Swift, William L. Irving	52
14	Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays 1996 ·Journal of Molecular Recognition ·Ralph Abraham, Sarah G. Buxbaum, John O. Link, Rodger Smith, (unknown), Michael J. Darsley	5
15	Screening and kinetic analysis of recombinant anti-CEA antibody fragments 1995 ·Journal of Immunological Methods ·Ralph Abraham, Sarah G. Buxbaum, John O. Link, Rodger Smith, (unknown), Michael J. Darsley	29
16	Aspects of antibody-catalyzed primary amide hydrolysis 1994 ·Applied Biochemistry and Biotechnology ·Richard C. Titmas, Thelma S. Angeles, Renee Sugasawara, (unknown), Michael J. Darsley, Gary F. Blackburn, Mark T. Martin	5
17	Conjugates of COL-1 monoclonal antibody and β-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug β-D-galactosyl-5-fluorouridine 1994 ·Cell Biochemistry and Biophysics ·Ralph Abraham, (unknown), (unknown), Michael J. Darsley, (unknown), John H. Kenten, Geoffrey N. Morris, Richard C. Titmas	24
18	Antibody-Catalyzed Hydrolysis of an Unsubstituted Amide 1994 ·Journal of the American Chemical Society ·Mark T. Martin, Thelma S. Angeles, Renee Sugasawara, (unknown), Andrew D. Napper, Michael J. Darsley, Rosa I. Sánchez, (unknown), Richard C. Titmas	53
19	Isoabzymes: Structurally and mechanistically similar catalytic antibodies from the same immunization 1993 ·Biochemistry ·Thelma S. Angeles, Rodger Smith, Michael J. Darsley, Renee Sugasawara, Rosa I. Sánchez, John H. Kenten, Peter G. Schultz, Mark T. Martin	30
20	New family of exon-shuffled recombinant genes reveals extensive interdomain interactions in class I histocompatibility antigens and identifies residues involved. 1987 ·The Journal of Experimental Medicine ·Michael J. Darsley, Hidemi Takahashi, M Macchi, Jeffrey A. Frelinger, Keiko Ozato, Ettore Appella	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact